Navigation Links
FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
Date:5/6/2011

MANHATTAN BEACH, Calif., May 6, 2011 /PRNewswire/ -- Yesterday, the U.S. Food and Drug Administration (FDA) approved the Novartis drug Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors.  Neuroendocrine tumors make up less than five percent of all pancreatic cancer diagnoses and are generally slower growing and less aggressive than the more common form of pancreatic cancer, pancreatic adenocarcinoma.

(Logo:  http://photos.prnewswire.com/prnh/20100914/MM64269)

"The FDA approval of Afinitor to treat pancreatic neuroendocrine tumors is welcome news for the pancreatic cancer community. For decades, treatment options for this insidious disease have been limited.  We are thrilled that patients with pancreatic neuroendocrine tumors now have another option when planning their course of treatment," stated Julie Fleshman, President and CEO of the Pancreatic Cancer Action Network.  

Afinitor® underwent rigorous clinical trials to determine the safety and effectiveness of the drug in this specific cancer type.  It was previously approved to treat other cancer types, but needed to prove effective in patients with pancreatic neuroendocrine tumors.  To this point, treatment options for pancreatic neuroendocrine tumors have not been well-established.  Patients have historically been treated with surgery, chemotherapies, and/or radiation.  In contrast to these treatment modalities, Afinitor® is a targeted therapy designed to attack specific proteins that are necessary for the growth of cancer cells.

"The Pancreatic Cancer Action Network encourages all patients to consider clinical trials when exploring treatment options. Clinical trials are a vital part of the research process and development of effective treatment options that will increase the survival rate of pancreatic cancer patie
'/>"/>

SOURCE Pancreatic Cancer Action Network
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 2015 Research and Markets ... "Diabetes Care Devices Market In Brazil, Russia, India ... Continuous Glucose Monitors, Testing Strips, Lancets, Insulin Pumps, Insulin ... to their offering. The BRIC diabetes care ... 1.7 Billion in 2015 and is poised to reach ...
(Date:9/3/2015)... 2015  VirtualScopics, Inc. (NASDAQ: VSCP ), ... announced today, they are collaborating with a large ... epidemiology study partnering with the Ministry of Health ... teamed up with a cardiac sonographer to acquire ... will be used to identify children with rheumatic ...
(Date:9/3/2015)... YORK , Sept. 3, 2015  The findings ... are raising disturbing questions about the company,s handling of ... LLP reports.  On September 2 nd , part ... 300 adverse events, including at least 27 fatalities, have ... disclosed a confidential study commissioned by C.R. Bard in ...
Breaking Medicine Technology:The BRIC Diabetes Care Devices Market is Estimated to Grow at a CAGR of 6.3% from 2015 to 2020, to Reach USD 2.3 Billion by 2020 2The BRIC Diabetes Care Devices Market is Estimated to Grow at a CAGR of 6.3% from 2015 to 2020, to Reach USD 2.3 Billion by 2020 3VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 2VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 3VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 4IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 2IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 3
... , MADISON, N.J., Nov. 2 Quest Diagnostics Incorporated ... diagnostic testing, information and services, announced that it is ... Conference in New York City. The presentation is ... Eastern Time. , During the conference, the company will ...
... Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it ... Monday, November 9, 2009, following the close of the U.S. financial ... 5:00 p.m. Eastern Time on the same day to discuss these ... available for two weeks following the event. The conference call, ...
Cached Medicine Technology:Quest Diagnostics To Speak At The Oppenheimer 20th Annual Healthcare Conference 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 3
(Date:9/3/2015)... ... September 03, 2015 , ... William Mattar Law Offices is ... believes this does not stop at any certain demographic or segment of the population. ... one-minute, thirty-, fifteen- and ten-second TV commercials. , The closed captioning will allow people ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... and Indiana University, Indianapolis, have chosen Center for Hospice Care (CHC) for ... institutions will train at CHC as part of fulfilling their requirements for obtaining ...
(Date:9/3/2015)... ... September 03, 2015 , ... Results of a comprehensive ... Research and Policy Analysis has found physician leadership development training programs to be ... of respondents said their organizations conduct some kind of physician leadership development program, ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... Florida Companies to Watch for 2015 by economic development group GrowFL ... only 50 companies in the state selected for this prestigious award, which recognizes ...
(Date:9/3/2015)... ... September 03, 2015 , ... Advice columnist, professional life ... debut book, “Stop Wasting Your Time Blaming Others for Your Life.” , Released ... to overcoming life’s obstacles by taking full responsibility for one’s life shares 15 ...
Breaking Medicine News(10 mins):Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 3Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3
... artemisinin-based combination therapies to prevent malaria //parasites from developing ... the National Agency for Food and Drug Administration and ... the parasite already has grown resistant to chloroquine and ... be difficult to find another malaria treatment. ...
... Court has issued notices to the state government and Delhi ... teacher at its Doha branch claiming Rs 1.5 million for ... after preliminary arguments on former teacher Vibha Kapur's plea, Justice ... chairman to file their replies by April 3. ...
... Hopkins Scleroderma Center together with engineers from the university's ... monitor that// checks a patient's finger for symptoms of ... device seem to be promising: ,The Ambulatory ... secured with a bandage or medical tape. It contains ...
... The U.S. Food and Drug Administration (FDA) today ... Complex (Human), Alphanate. //The product is approved for ... Willebrand disease (vWD) in whom the hormone desmopressin ... approved for patients with severe vWD (Type 3) ...
... All India Institute of Medical Sciences (AIIMS) director P. ... public relation officer filed a police complaint against him. ... relation officer of AIIMS, has filed a police complaint ... accusing Venugopal of harassment, wrongful restraint from entering office, ...
... British scientists have developed a house to help people with ... a warning when it thinks there may be a problem. ... Institute of Medical Engineering could mean elderly people with fading ... rather than being forced to go into care homes, reported ...
Cached Medicine News:Health News:Ex-teacher Sues Delhi Public School 2Health News:Space-Age Bandage Monitors Patients With Raynaud's Disease 2Health News:FDA Approves New Product to Treat Von Willebrand Disease 2Health News:AIIMS Official Files Complaint Against Venugopal 2Health News:‘Smart House’ Developed to Monitor People With Dement 2
Farabeuf periosteal elevators....
OHL periosteal elevator, 19 cm, 7-1/2"....
Steinhauser periosteal elevator....
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Medicine Products: